Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 411

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 411
---
ance of Common Stock

In 2022, we issued 15,367 shares of our common stock to Rivopharm S.A., or Rivopharm, in lieu of cash payment for work performed by a
subsidiary of Rivopharm, pursuant to an oral agreement between us and an affiliate of Rivopharm. For additional information, see “Certain Relationships and Related Party Transactions—Issuance of Common Stock.”

Issuances Pursuant to our Equity Plans

From January 1, 2022 through the date of this registration statement, we have granted options under our 2023 Stock Incentive Plan to
purchase up to an aggregate of 424,904 shares (net of expirations, forfeitures and cancellations) of common stock, at a weighted-average price of $41.84 per share, in each case, to our employees, directors and consultants. From January 1, 2022
through the date of this registration statement, no options have been granted under our 2017 Stock Incentive Plan or 2018 Stock Incentive Plan, and no shares of common stock have been issued upon the exercise of options.

Issuances of Warrants

In May
2022, we issued the Series B-1 Warrants to certain accredited investors to purchase 3,708 shares of our common stock at an exercise price per share of $104.58.

In August 2023, we issued the Maxim Warrants to Maxim Group LLC to purchase 54,813 shares of our common stock at an exercise price per share
of $0.28.

In August 2023, we issued the New Series B Warrants to certain accredited investors to purchase 3,577 shares of our common
stock at an exercise price per share of $41.84.

Issuances of Preferred Stock

In May 2022, we issued 301,119 shares of our Series B preferred stock to certain individual and institutional accredited investors at a
purchase price of $3.00 per share, for aggregate consideration of approximately $0.9 million, or the Series B Offering. Maxim Group LLC acted as placement agent for the Series B Offering and received a commission of up to 10.0% of the gross
proceeds from the Series B Offering and certain warrants which were ultimately replaced with the Maxim Warrants.

From August 2023 to
January 2024, we issued 50,000,000 shares of our Series C preferred stock to 234